載入中
Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. It is also developing preclinical assets, including IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, such as IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.
一般交易時段
US$19.455
−US$0.095 · -0.49%
盤中時間採用ET。市場資料可能有所延遲。
Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. It is also developing preclinical assets, including IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, such as IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.
日內區間
目前US$19.455
52週區間
目前US$19.455
盤中時間採用ET。市場資料可能有所延遲。
Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. It is also developing preclinical assets, including IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, such as IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.
日內區間
目前US$19.455
52週區間
目前US$19.455
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 694.1萬 USD | 904.1萬 USD | 1401.8萬 USD | — | — |
| 銷貨成本 | 295.5萬 USD | — | — | — | — |
| 毛利 | 398.6萬 USD | 904.1萬 USD | 1401.8萬 USD | — | — |
| 研究與開發 | 1.74億 USD | 1.3億 USD | 2308.9萬 USD | 2327.2萬 USD | 1411萬 USD |
| 銷售、一般及管理費用 | 4376.8萬 USD | 3295.5萬 USD | 1965.7萬 USD | 1362.9萬 USD | 1109.4萬 USD |
| 營業費用 | 2.18億 USD | 3.15億 USD | 1.24億 USD | 3690.1萬 USD | 2520.4萬 USD |
| 利息收入 | 1171.9萬 USD | 1283.7萬 USD | 272.4萬 USD | 5000 USD | 1萬 USD |
| 利息支出 | — | — | — | 5000 USD | 1萬 USD |
| 折舊和攤銷 | 295.5萬 USD | 210.2萬 USD | 72.8萬 USD | 63.1萬 USD | 75.5萬 USD |
| 營業利益 | −2.14億 USD | −3.06億 USD | −1.1億 USD | −3690.1萬 USD | −2520.4萬 USD |
| 淨利 | −2.12億 USD | −2.93億 USD | −1.07億 USD | −3689.6萬 USD | −2471.1萬 USD |
公司資料更新於 2026年10月12日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$33.00
上漲空間 69.62%報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI8865.93萬0.00%2.3兆 USD0.03%US$381.67-0.07%
iShares Russell 2000 ETFIWM5383.39萬0.07%787.4億 USD0.19%US$278.45-0.17%
State Street SPDR S&P Biotech ETFXBI3818.8萬0.39%98.74億 USD0.35%US$152-1.15%
Vanguard Extended Market ETFVXF3393.48萬0.03%954億 USD0.05%US$234.01-0.42%
iShares Russell 2000 Growth ETFIWO1904.98萬0.14%139.17億 USD0.24%US$354.56-0.62%
Vanguard Russell 2000 ETFVTWO1660.69萬0.09%180億 USD0.06%US$112.48-0.16%
Schwab U.S. Small-Cap ETFSCHA1160.59萬0.05%218.24億 USD0.03%US$32.745-0.14%
Vanguard Health Care ETFVHT805.53萬0.04%220億 USD0.09%US$319.6+0.18%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMState Street SPDR S&P Biotech ETFXBIVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHAVanguard Health Care ETFVHTAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
